The main objective of this study was to assess whether aspirin 100 mg QD can improve blood pressure (BP) control and endothelial function in subjects with arterial hypertension (AH) and hypercholesterolaemia. In total, 21 patients of both sexes (52.1711.5 years) with treated AH and hypercholesterolaemia on antihypertensive and statin therapy were included in the treatment group. In the control group, 20 matched patients of both sexes (51.3712.7 years), but without statin therapy, were recruited. Treatment group subjects received aspirin (100 mg QD) for a duration of 12 weeks at randomization (Treatment phase-1), followed by single blind matching placebo for 12 weeks (Placebo phase) and then again received aspirin (100 mg QD) for an additional 12 weeks (Treatment phase-2). The control group participated in Treatment phase-1, but did not continue Placebo phase and Treatment phase-2. At randomization and at the end of each study phase, mean 24-h systolic BP (SBP) and diastolic BP (DBP) were assessed by 24-h ambulatory blood pressure monitoring (ABPM) and endotheliumdependent (flow mediated, FMD) and -independent (nitroglycerin induced, NTG) vasodilatations of brachial artery were measured using high-resolution ultrasound. In Treatment phase-1, reduction of SBP and DBP (DSBP 5.772.6 mmHg, P ¼ 0.008; DDBP 3.871.7 mmHg, P ¼ 0.014) and improvement of FMD (4.170.6%, P ¼ 0.019), in Placebo phase an elevation of SBP and DBP (DSBP À6.272.9 mmHg, P ¼ 0.002; DDBP À4.271.9 mmHg, P ¼ 0.031) and worsening of FMD (À3.870.9%, P ¼ 0.027), and in Treatment phase-2 reduction of SBP and DBP (DSBP 4.972.3 mmHg, P ¼ 0.005; DDBP 4.171.3 mmHg, P ¼ 0.024) and improvement of FMD (4.571.3%, P ¼ 0.009) were observed in the treatment Group but not in the control group. Addition of low-dose aspirin to antihypertensive medications and statins in hypertensive and hypercholesterolaemic subjects can reduce both SBP and DBP by improvement of endothelial function.
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Introduction
Acetyl-salicylic acid (aspirin) use in hypertensive patients is expected to increase after the publication of the results from the Hypertension Optimal Treatment (HOT) study, which documented the efficacy of low-dose aspirin in preventing major cardiovascular events in hypertensive subjects. 1 Although aspirin is the most frequently used medication for the prevention of cardiovascular diseases, [2] [3] [4] few reports exist about its influence on blood pressure (BP) control in hypertensive subjects. [5] [6] [7] These studies have shown no influence of low-dose aspirin on BP in hypertensive patients 8, 9 (Table 1) . Other nonsteroidal antiinflammatory medications (NSAIDs) have been shown be able to increase BP both in normotensive and hypertensive subjects 5, [10] [11] [12] and this BP elevating effect of NSAIDs appears more marked in hypertensive subjects under treatment. 5, 10 Aspirin's BP effect is dose dependent, as well as on the time of administration, as was shown in clinically healthy volunteers and in patients with untreated mild hypertension. 7 Aspirin, regularly used for prevention of cardiovascular events, is usually coadministered with other (antihypertensive and lipid lowering) medications and its dose is markedly lower than the dose recommended for its anti-inflammatory effects. [13] [14] [15] Whether low-dose aspirin can modulate the known beneficial effects of statins on BP and endothelial function is not known.
The current study aimed to investigate the influence of the addition of low-dose aspirin (100 mg QD) on 24-h BP and brachial artery flowmediated vasodilatation (FMD) in hypertensive and hypercholesterolaemic patients with and without statin therapy. Therefore, we coadministered the two medications in hypertensive and hypercholesterolaemic patients and chose the control arm of hypertensive and hypercholesterolaemic patients without statin therapy (and thus to have a higher cholesterol value than the treatment arm).
Methods

BP measurements
The systolic BP (SBP), diastolic BP (DBP), and heart rate (HR) of each patient were automatically measured every 20 min during the day (0700-2300 hours) and every 30 min during the night for 24 consecutive hours using a validated 'Profilomat' device (Dinamap Co. Ltd, USA). The first BP measurement was performed at the medical setting to validate the proper functioning of the ambulatory blood pressure monitoring (ABPM) device and to check the accuracy by comparison of BP readings with those obtained by the office device. Patients were assessed while adhering to their usual diurnal activity (0800-2300 hours for most)-nocturnal sleep routine. They were instructed to go about their usual activities with minimal restrictions but to follow a similar schedule during the 2 days of ABPM. None of the subjects was hospitalized during monitoring. BP series were eliminated from analysis when they did not contain at least 70% of valid measurements and when the subjects showed an irregular restactivity schedule during the 24 h of sampling, an odd sampling with spans of 43 h without BP measurement or a night resting span o6 or 412 h.
The 24-h average BP value was evaluated from total measured values.
Endothelium-dependent and -independent vasodilatations of brachial artery
Endothelium-dependent (flow-mediated, FMD) and -independent (nitroglycerin-induced, NTG) vasodilatations of brachial artery were measured by the same examiner. The measurements were performed according to the guidelines. 16 The arterial diameter was measured using an ultrasonic phase-locked echo-tracking system, which was equipped with a high-resolution, real-time 7.5-MHz linear scanner in B-mode (SSD 610; Aloka, Tokyo), to obtain longitudinal images of the brachial artery at a marked point 5-10 cm proximal to the antecubital fossa on the dominant arm. Patients underwent imaging in a supine position after at least 15 min of equilibration in a climate-controlled environment. All the subjects were fasted for at least 8 h before the study. They were also instructed to abstain from cigarette smoking before the study. Two-dimensional images were obtained at baseline with Doppler ultrasound scanning to assess arterial diameter and flow velocity. Angle correction software was used during Doppler imaging to approximate a 201 angle of incidence to blood flow. Colourflow Doppler imaging was also used to localize arterial flow before measuring Doppler velocities and to confirm the cessation and resumption of flow with cuff occlusion and reactive hyperemia, respectively. Images were acquired with electrocardiogram gating, with measurements made in end diastole. Increased shear stress was achieved by producing reactive hyperemia. After inflating a blood pressure cuff to 200 or 50 mmHg above systolic pressure for 5 min, arterial diameter and flow velocity measurements were made 60 s after cuff deflation. Arterial diameter was measured from the near to the far wall Table 1 Previous studies of low-dose aspirin on BP
Low-dose aspirin on BP in hypertensive patients
Benefits of the studies Limitations of the studies
The HOT study 1 Documented the efficacy of low-dose aspirin in preventing major cardiovascular events in hypertensive subjects
Evaluation of influence of low-dose aspirin on BP was an objective of the study Few reports exist of positive influence of low-dose aspirin on BP control in hypertensive subjects. [5] [6] [7] Other studies have shown no influence of low-dose aspirin on BP in hypertensive patients 8, 9 Influence of aspirin on BP was found to be dose and administration-time dependent Heterogeneity of the studied populations (ischaemic heart disease, diabetes, hypercholesterolaemia, concomitant medications) Low-dose aspirin can modulate endothelial dysfunction Investigation of possible mechanisms, by which low-dose aspirin can influence on BP of patients with AH and hypercholesterolaemia Improvement of endothelial function was shown in acute studies, 28, 29 while results of chronic trials are conflicting [30] [31] [32] Our study demonstrates that addition of low-dose aspirin in hypertensive and hypercholesterolaemic subjects on top of antihypertensive and statins improves endothelial function and reduces BP Homogeneity of the studied population. Demonstration of synergistic interactions between aspirin and statins on BP reduction via improvement of NOmediated endothelial function Small study. Other possible mechanisms of the observed synergistic interactions between aspirin and statins were not investigated Effects of low-dose aspirin on BP and endothelial function E Magen et al at the intima-media interface or to the clearest echocardiography line. The mean values of 3-5 measurements were averaged for each datum point, and results were expressed as change in arterial diameter divided by baseline diameter. Thereafter, 15 min was allowed for recovery of the vessel, after which sublingual nitroglycerin (0.5 mg) was administered and imaging was repeated to document flow-independent vasodilatation. After 12 weeks of treatment with aspirin, 12 weeks of placebo and again after 12 weeks of aspirin, patients returned for reassessment of endotheliumdependent and -independent vasodilatation.
Study protocol
The study was a single blind, placebo-controlled trial, conducted at the World Health Organization Collaborative Center for Prevention of Cardiovascular Diseases, Barzilai Medical Center, Israel. The local ethics committee approved the protocol and all the participants gave written informed consent according to Helsinki Guidelines.
In total, 21 patients of both sexes (52.1711.5 years) with treated arterial hypertension (AH) and hypercholesterolaemia (at least for the period of 3 months prior to randomization) were included in the treatment group. In the control group, 20 matched patients of both sexes (51.3712.7 years) with treated AH (at least for the period of 3 months prior to randomization) and hypercholesterolaemia, treated with diet (without statin therapy) were recruited. The participants enrolled into the study had to fulfill the following inclusion criteria:
(1) Essential hypertension treated with BP lowering medications for at least 6 months and an average SBP4130 mmHg and/or an average DBP480 mmHg measured by 24 h ABPM. (2) Hypercholesterolaemia treated with any lipidlowering drug for at least 6 months before the study entry.
Exclusion criteria were:
(1) Use of long-acting nitrates or NSAID (2) Insulin-dependent diabetes mellitus (3) Fasting hyperglycaemia4180 mg/dl (4) Liver or kidney disease (by history or blood examination tests) (5) Cancer (6) Ischaemic heart disease Routine blood examination tests and a physical examination were performed to exclude other comorbid conditions. The patients in the treatment group received aspirin (100 mg QD at 0900 hours) for a duration of 12 weeks at randomization (Treatment phase-1), followed by single blind matching placebo for 12 weeks (Placebo phase) and then again received aspirin (100 mg QD) for an additional 12 weeks (Treatment phase-2). The patients in the control group also received aspirin (100 mg QD at 0900 hours) for a duration of 12 weeks in a randomization, but did not continue the 12 weeks placebo and the12 weeks repeated aspirin treatment periods. Concomitant medications remained unchanged throughout the study course.
Statistical analysis
Results are presented as mean7s.e.m. Measurements of FMD-and GTN-induced vasodiltation Effects of low-dose aspirin on BP and endothelial function E Magen et al represent the maximal increase in brachial diastolic arterial diameter and are expressed as percent change from baseline. To differentiate between variables under aspirin and placebo, we used twotailed paired Student's t test (software Statistica 6, StatSoft Inc. USA). A value of Po0.05 was considered significant.
Results
A total of 21 patients were included in the treatment group and 20 in the control group. All of them completed the study. Baseline demographic and clinical characteristics of the patients are presented in Table 2 .
Effect of aspirin on BP
Treatment group
In the treatment group, the baseline SBP and DBP were 138.676.2 and 79.178.5 mmHg, respectively (Table 1) . After 12 weeks, aspirin significantly decreased SBP and DBP (DSBP 5.772.6 mmHg, P ¼ 0.008; DDBP 3.871.7 mmHg, P ¼ 0.014). When aspirin was replaced with placebo for 12 weeks, an elevation of both SBP and DBP was observed (DSBP À6.272.9 mmHg, P ¼ 0.002; DDBP À4.271.9 mmHg, P ¼ 0.031); replacing placebo with aspirin for 12 weeks caused reduction of both SBP and DBP (DSBP 4.972.3 mmHg, P ¼ 0.005; DDBP 4.171.3 mmHg, P ¼ 0.024) (Figure 1a) . HR, total cholesterol, LDL, glucose, and creatinine remained unaltered throughout the study.
Control group
No statistically significant changes of SBP and DBP were observed in the control group after 12 weeks of aspirin therapy (Figure 1b) .
Effects of aspirin on vascular function
Treatment group
In the treatment group, brachial artery FMD was significantly increased with aspirin (4.170.6%, P ¼ 0.019) after 12 weeks of therapy (Treatment phase-1), while discontinuation of aspirin and treatment with placebo for 12 weeks caused lowering of FMD to the pretreatment level (À3.870.9%, P ¼ 0.027) (Placebo phase). Shifting from placebo to aspirin once again for 12 weeks elevated FMD (4.571.3%, P ¼ 0.009) (Treatment phase-2). GTNinduced vasodilatation remained unchanged (aspirin 9.471.5% vs placebo 9.671.8%; P ¼ 0.74 and then placebo vs aspirin 9.371.7%; P ¼ 0.59) as did average baseline diameter (aspirin treatment for 12 weeks 41767164; P ¼ 0.036-placebo for 12 weeks À43947116 mm; P ¼ 0,019-aspirin for 12 weeks 44717229; P ¼ 0.029) (Figure 1c ).
Control group
In the control group, 12-week aspirin did not cause statistically significant changes in both brachial artery FMD and NTG (Figure 1c) .
Discussion
This study demonstrates that addition of low-dose aspirin in hypertensive and hypercholesterolaemic subjects on top of standard therapy improves endothelial function and reduces BP. Similar effects of bedtime low-dose aspirin on BP were observed in a study on pregnant women, 7 but another study 8 did not find any significant influence of 3 months treatment with morning low-dose aspirin on BP control in treated hypertensive subjects. There may be several reasons why our study has shown a change in BP, when other studies in the past have not done so. First, our patients were on statin therapy for at least 6 months before the study entry; second, we excluded hyperglycemic subjects. Beneficial effects of statins on BP control and endothelial function are well established. 17, 18 However, the concomitant medications including statins were not changed throughout the study period. Thus, improvement of BP control and brachial artery FMD in the treatment group may be explained by low-dose aspirin administration. Although positive interaction between aspirin and losartan was shown in one study, 19 other investigators did not find any significant interference of aspirin with the BP-lowering effect of antihypertensive agents, including combinations with ACE inhibitors. [20] [21] [22] [23] It is unlikely that improvement of BP control and endothelial function in our patient was caused by cyclooxygenase (COX) inhibition. Nonselective COX inhibition is associated with antinatriuretic and vasoconstrictor effects. 24, 25 Actually, this may affect BP control in patients with hypertension, especially when hypertension is controlled by drugs that block the rennin-angiotensin system or require prostaglandin-I2 (PGI2) or bradykinin formation for their complete antihypertensive effectiveness. [23] [24] [25] [26] [27] It is of note that low-dose aspirin, at least in acute studies, improves endothelial function in patients with hypercholesterolaemia 28 and atherosclerosis. 29 Results of chronic trials are conflicting. [30] [31] [32] Since other COX inhibitors showed no beneficial vascular effects, aspirin might exhibit a vasculoprotective, COX-independent mechanism. Recently, Taubert et al 33 demonstrated that therapeutically relevant concentrations of aspirin elicit nitric oxide (NO) release from vascular endothelium due to a direct acetylation of the eNOS protein, but is independent of COX inhibition or inhibition of superoxidemediated NO degradation. Another group found that aspirin did not have a significant effect on the NO bioavailability in endothelial cells, but it can highly improve NO production in platelets. The high NO production in platelets may counteract the Effects of low-dose aspirin on BP and endothelial functioneffect of thromboxane, inhibit platelet aggregation, and compensate for the reduction of prostacycline concentration by aspirin. 34 Regrettably, we did not perform platelet studies to check if the improvement in endohtelial function was related to the extent of reversal of platelet functions.
Since the reduction of vascular inflammation and oxidative stress has been well documented to contribute to the beneficial prognostic effects of statins, 35 aspirin's ability to modulate inflammatory mediators (prostaglandins, reactive oxygen species) 36 may further enhance the anti-inflammatory effects of statins and contribute to improvement of endothelial function. This hypothesis we formulated after we just happened to find that in those with high cholesterol and without statin therapy, there was no change of endothelial function with aspirin.
In conclusion, the findings of the present study show that low-dose aspirin coadministered with statins improves NO-mediated endothelial function, and when administered without statins does not, are of particular clinical interest. It demonstrates that aspirin plus statins are better than aspirin or statin alone, and this combination holds the potential to beneficially impact atherosclerotic vascular disease by improving a well-established clinically useful surrogate for cardiovascular disease. Further studies are needed to elucidate possible mechanisms of the observed synergistic interactions between aspirin and statins.
